Adam Płużański
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 30
- Lung Cancer Diagnosis and Treatment 9
- Gastric Cancer Management and Outcomes 5
- Tracheal and airway disorders 3
- Oncology 32
- Cancer Immunotherapy and Biomarkers 18
- Colorectal Cancer Treatments and Studies 7
- Lung Cancer Research Studies 3
- Co-authors
- Tony S.K. Mok (8 shared papers)Yi-Long Lung Cancer Wu (8 shared papers)Jesus Corral (7 shared papers)Ki Hyeong Lee (6 shared papers)Kazuhiko Nakagawa (7 shared papers)R Cebolla Rosell (6 shared papers)Maria Rita Migliorino (5 shared papers)Xiangdong Zhou (6 shared papers)
- Journals
- Annals of Oncology (7 papers)Cancers (6 papers)Journal of Thoracic Oncology (6 papers)Journal of Clinical Oncology (4 papers)Future Oncology (3 papers)
- Partner nations
- PolandUnited StatesSpain
In The Last Decade
Adam Płużański
54 papers receiving 13.5k citations
Adam Płużański's Hit Papers
Peers
Comparison fields: 5 of 114
- Oncology 9.5k
- Pulmonary and Respiratory Medicine 5.3k
- Immunology 2.2k
- Cancer Research 1.3k
- Genetics 324
Countries citing papers authored by Adam Płużański
This map shows the geographic impact of Adam Płużański's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Płużański with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Płużański more than expected).
Fields of papers citing papers by Adam Płużański
This network shows the impact of papers produced by Adam Płużański. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Płużański. The network helps show where Adam Płużański may publish in the future.
Co-authors
The 25 scholars most cited alongside Adam Płużański, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 7150 |
| 2 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Hit paper breakdown → | 2018 | 2504 |
| 3 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 995 |
| 4 | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Hit paper breakdown → | 2017 | 736 |
| 5 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 477 |
| 6 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations Hit paper breakdown → | 2018 | 376 |
| 7 | Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 Hit paper breakdown → | 2022 | 299 |
| 8 | 2019 | 281 | |
| 9 | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial Hit paper breakdown → | 2021 | 252 |
| 10 | 2014 | 127 | |
| 11 | 2020 | 94 | |
| 12 | 2023 | 58 | |
| 13 | 2019 | 44 | |
| 14 | 2023 | 42 | |
| 15 | 2016 | 39 | |
| 16 | 2019 | 34 | |
| 17 | 2022 | 30 | |
| 18 | 2020 | 24 | |
| 19 | 2021 | 24 | |
| 20 | 2022 | 24 |
About Adam Płużański
Adam Płużański is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Genetics and Cancer Research, having authored 58 papers that have together received 13.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Diagnosis and Treatment (9 papers), Colorectal Cancer Treatments and Studies (7 papers), Salivary Gland Tumors Diagnosis and Treatment (6 papers), Gastric Cancer Management and Outcomes (5 papers), Tracheal and airway disorders (3 papers) and Lung Cancer Research Studies (3 papers). The work is most often cited by research in Oncology (9.5k citations), Pulmonary and Respiratory Medicine (5.3k citations), Immunology (2.2k citations), Cancer Research (1.3k citations) and Genetics (324 citations). Adam Płużański has collaborated with scholars based in Poland, United States and Spain. Frequent co-authors include Tony S.K. Mok, Yi-Long Lung Cancer Wu, Jesus Corral, Ki Hyeong Lee, Kazuhiko Nakagawa, R Cebolla Rosell, Maria Rita Migliorino, Xiangdong Zhou, Seiji Niho and Ying Cheng. Their work appears in journals such as Annals of Oncology, Cancers, Journal of Thoracic Oncology, Journal of Clinical Oncology and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.